NCT00493077CompletedPhase 4
A Swedish Multi-Centre, Prospective, Open Label Study: Safety of Avonex Treatment in Multiple Sclerosis Patients Who Are NAB Positive on Previous s.c Interferon Beta Therapy
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Biogen
- Enrollment
- 3
- Locations
- 2
- Primary Endpoint
- neutralizing antibody levels will be followed
Study Overview
Brief Summary
This study is to find out the safety and effectiveness of Avonex (interferon-beta-1a) Therapy in patients who have developed neutralizing antibodies during previous interferon-beta treatment
Detailed Description
This is a multi-centre, prospective, open label, non-comparative phase IV trial. Eligible patients will receive treatment with IFN-beta-1a AVONEX® 30 mcg i.m. once weekly for 12 months.The patients will be examined clinically and NAb titres will be performed at screening and after 12 months. Adverse event source verification will be performed during the documentation period.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Relapsing-remitting MS according to Poser criteria(CDMS or LSDMS)30 or MS according to McDonald criteria
- •Disability equivalent to an EDSS of 6.0 or less at screening
- •Neutralizing antibody titre > 20 and <500 in two consecutive NAb tests. One must be from before screening
- •previous treatment with either subcutaneous administered interferon-b-1b (Betaferon®) or interferon-b-1a (Rebif TM) prior to enrolment
- •A priori has been decided to be treated with AVONEX
Exclusion Criteria
- •Is NAb positive on AVONEX
- •History of major depression
- •Cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or advanced ischemic heart disease (NYHA III or IV), or significant hypertension (BP > 180/110 mmHg)
- •Renal insufficiency defined as serum creatinine > 1.5 times the upper normal reference limit
- •Any systemic disease that can influence the patient's safety and compliance, or the evaluation of the disability
- •Women who are pregnant, breast-feeding or have the possibility for pregnancy during the trial. To avoid pregnancy, women have to be postmenopausal, surgical sterile, sexually inactive or practice reliable contraceptives
Arms & Interventions
1
Experimental
Intervention: low immunogenic interferon-beta-1a (Drug)
Outcomes
Primary Outcomes
neutralizing antibody levels will be followed
Time Frame: 12 months
Secondary Outcomes
- Proportion of patients with NAb positive titre > 20.(12 months)
- Relative change from baseline (screening) of NAb titre(12 months)
- Change in the annualised relapse rate and number of relapse-free (total and documented relapses) patients(12 months and as needed for relapses)
- The percentage of patients with a loss of disability of 1.0 (or more) score on the EDSS.(12 months)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Terminated
Phase 3
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) PatientsMultiple SclerosisNCT00784836Biogen3
Completed
Phase 4
Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple SclerosisMultiple SclerosisNCT00037102MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute16
Completed
Phase 2
Interferon-beta1a (AVONEX) Treatment of Ulcerative ColitisUlcerative ColitisNCT00048347National Institute of Allergy and Infectious Diseases (NIAID)18
Completed
Phase 2
Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Chronic Inflammatory Demyelinating PolyradiculoneuropathyNCT00099489Biogen67
Completed
Phase 2
Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative ColitisUlcerative ColitisNCT00303381EMD Serono194